title: 1H MRS studies in the Finnish boron neutron capture therapy project: detection of 10B-carrier, L-p-boronophenylalanine-fructose.
abstract: This article summarizes the current status of 1H MRS in detecting and quantifying a boron neutron capture therapy (BNCT) boron carrier, L-p-boronophenylalanine-fructose (BPA-F) in vivo in the Finnish BNCT project. The applicability of 1H MRS to detect BPA-F is evaluated and discussed in a typical situation with a blood containing resection cavity within the gross tumour volume (GTV). 1H MRS is not an ideal method to study BPA concentration in GTV with blood in recent resection cavity. For an optimal identification of BPA signals in the in vivo 1H MR spectrum, both pre- and post-infusion 1H MRS should be performed. The post-infusion spectroscopy studies should be scheduled either prior to or, less optimally, immediately after the BNCT. The pre-BNCT MRS is necessary in order to utilise the MRS results in the actual dose planning.
authors.affiliation: Department of Physical Sciences, University of Helsinki, POB 64, FIN-00014, Helsinki, Finland.
authors.forename: M
authors.initials: M
authors.lastname: Timonen
authors.forename: L
authors.initials: L
authors.lastname: Kankaanranta
authors.forename: N
authors.initials: N
authors.lastname: Lundbom
authors.forename: J
authors.initials: J
authors.lastname: Collan
authors.forename: A
authors.initials: A
authors.lastname: Kangasmäki
authors.forename: M
authors.initials: M
authors.lastname: Kortesniemi
authors.forename: A-M
authors.initials: AM
authors.lastname: Häkkinen
authors.forename: A
authors.initials: A
authors.lastname: Lönngren
authors.forename: S
authors.initials: S
authors.lastname: Karjalainen
authors.forename: M
authors.initials: M
authors.lastname: Rasilainen
authors.forename: J
authors.initials: J
authors.lastname: Leinonen
authors.forename: T
authors.initials: T
authors.lastname: Huitti
authors.forename: J
authors.initials: J
authors.lastname: Jääskeläinen
authors.forename: M
authors.initials: M
authors.lastname: Kouri
authors.forename: S
authors.initials: S
authors.lastname: Savolainen
authors.forename: S
authors.initials: S
authors.lastname: Heikkinen
mesh_terms: D000328:Adult; D000368:Aged; D001895:Boron / Q000627:therapeutic use; D001896:Boron Compounds / Q000032:analysis / Q000097:blood*; D016754:Boron Neutron Capture Therapy; D001932:Brain Neoplasms / Q000473:pathology / Q000532:radiotherapy; D002277:Carcinoma / Q000473:pathology / Q000532:radiotherapy; D005260:Female; D005387:Finland; D005632:Fructose / Q000031:analogs & derivatives* / Q000032:analysis / Q000097:blood; D005909:Glioblastoma / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D006859:Hydrogen; D007554:Isotopes / Q000627:therapeutic use; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000532:radiotherapy; D010255:Paranasal Sinus Neoplasms / Q000473:pathology / Q000532:radiotherapy; D019047:Phantoms, Imaging; D010949:Plasma; D019275:Radiopharmaceuticals / Q000627:therapeutic use
chemical_list: C089739:4-boronophenylalanine-fructose; D001896:Boron Compounds; D007554:Isotopes; D019275:Radiopharmaceuticals; D005632:Fructose; D006859:Hydrogen; D001895:Boron